The addition of chemotherapy and anti-EGFR monoclonal antibody (Mab) treatment improves the local control rate (LCR) and the overall survival rate (OS) for advanced NPC patients (3, 4). This evidence concerns the gene EGFR and nasopharyngeal carcinoma.